United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $6.73 per share and revenue of $814.8010 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 9:00 AM ET.

United Therapeutics Stock Up 1.8%

NASDAQ UTHR opened at $482.42 on Wednesday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $519.99. The business has a fifty day moving average of $486.02 and a 200-day moving average of $437.28. The stock has a market cap of $20.77 billion, a price-to-earnings ratio of 18.28, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $473.66, for a total value of $10,657,350.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 450,714 shares of company stock valued at $218,011,238 in the last 90 days. 10.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of UTHR. Stirlingshire Investments Inc. acquired a new stake in United Therapeutics during the 4th quarter valued at $236,000. Dorsey & Whitney Trust CO LLC acquired a new position in United Therapeutics in the 4th quarter worth $212,000. Lido Advisors LLC purchased a new position in United Therapeutics in the 3rd quarter valued at about $241,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of United Therapeutics during the second quarter valued at about $214,000. Finally, Transamerica Financial Advisors LLC grew its stake in shares of United Therapeutics by 57.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 169 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on UTHR shares. UBS Group restated a “buy” rating on shares of United Therapeutics in a report on Tuesday. HC Wainwright boosted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.